Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have a history of seasonal allergic rhinitis~* Have a positive (as defined in the protocol) skin prick or RAST test within 12 months prior to the screening visit~Exclusion Criteria:~* Have a clinically significant illness or disease~* Have unstable asthma~* Has participated in a clinical trial 30 days prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bilastine 20 mg
- 2 (Type: ACTIVE_COMPARATOR): Fexofenadine 120 mg
- 3 (Type: ACTIVE_COMPARATOR): Cetirizine 10 mg
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).